You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-androgen receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Castration-resistant Prostate Cancer Trial (ONC-392, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • ONC-392
  • lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
  • (no location specified)
Dec 27, 2022

Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial

Not yet recruiting
  • Locally Advanced Salivary Gland Carcinoma
  • +3 more
  • Biopsy
  • +3 more
  • (no location specified)
Jan 10, 2023

Prostate Cancer Trial in Boston, Brooklyn, New York (225Ac-J591, Pembrolizumab, Androgen receptor pathway inhibitor)

Recruiting
  • Prostate Cancer
  • Boston, Massachusetts
  • +3 more
Sep 20, 2021

Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma Trial in San Francisco (Apalutamide, Cetrelimab)

Recruiting
  • Small Cell Neuroendocrine Carcinoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Mar 21, 2022

Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer Trial in

Recruiting
  • Castration-Resistant Prostatic Cancer
  • +4 more
  • Orange City, Florida
  • +1 more
Nov 23, 2022

Malignant Tumor Trial in United States (Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration)

Recruiting
  • Malignant Neoplasm
  • Danville, Illinois
  • +5 more
Apr 13, 2022

Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Trial in Madison (18F-DCFPyL)

Recruiting
  • Breast Cancer
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin School of Medicine and Public Health
Oct 18, 2022

Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide

Not yet recruiting
  • Prostate Adenocarcinoma
  • +2 more
  • Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
  • Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 4, 2023

Breast Cancer With or Without BRCA Mutation

Recruiting
  • Breast Cancer
  • Androgen receptor status and BRCA mutation
  • Varanasi, UP, India
    Banaras Hindu University
Jun 2, 2022

Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston

Recruiting
  • Advanced Breast Carcinoma
  • +17 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

Not yet recruiting
  • Urothelial Carcinoma Bladder
  • Androgen Receptor Positive
  • Providence, Rhode Island
    Lifespan Cancer Institute
May 1, 2023

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of

Not yet recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 25, 2023

Physical Function During ARSI Treatment

Recruiting
  • Advanced Prostate Carcinoma
  • androgen receptor signaling inhibitors
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Nov 8, 2022

Salivary Gland Carcinoma Trial in United States (Goserelin Acetate, Pembrolizumab)

Recruiting
  • Salivary Gland Carcinoma
  • Chicago, Illinois
  • +6 more
Sep 22, 2022

Breast Cancer Trial in Beijing, Zhengzhou, Changsha (EG017)

Not yet recruiting
  • Breast Cancer
  • Beijing, Benjing, China
  • +2 more
Dec 30, 2022

Androgen Deprivation Therapy, Prostate Cancer, Hypertension Trial (Gonadotropin-Releasing Hormone Agonist, Androgen receptor

Not yet recruiting
  • Androgen Deprivation Therapy
  • +4 more
  • Gonadotropin-Releasing Hormone Agonist
  • +2 more
  • (no location specified)
Jan 18, 2023

Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)

Active, not recruiting
Has Results
  • Androgen Receptor Positive
  • +5 more
  • Corona, California
  • +6 more
Jun 8, 2022

Androgen Receptor Polymorphism on Endometrial Cancer

Not yet recruiting
  • Androgen Receptor Abnormal
  • Endometrial Disorder
  • Endometrial sampling and Peripheral blood collection
  • FSFI Scale
  • (no location specified)
Dec 12, 2021

Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Trastuzumab Deruxtecan
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023

Salivary Gland Cancer Trial in Japan (Darolutamide, Goserelin)

Recruiting
  • Salivary Gland Cancer
  • Nagoya, Aichi, Japan
  • +11 more
Jan 21, 2023

Prostatic Tumor Trial (AAA617, AAA517, Piflufolastat F 18)

Not yet recruiting
  • Prostatic Neoplasm
  • (no location specified)
Apr 27, 2023

Prostatic Tumors Trial in Beijing, NanJing, ShangHai (Apalutamide)

Active, not recruiting
  • Prostatic Neoplasms
  • Beijing, China
  • +3 more
Jan 17, 2023

Prostate Cancer, Malignant Tumor of Prostate, Secondary Malignant Tumor of Prostate Trial in Cleveland (drug, other, radiation)

Not yet recruiting
  • Prostate Cancer
  • +2 more
  • Androgen deprivation therapy (ADT)
  • +3 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center Seidman Cancer Cen
Nov 21, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 23, 2023

Prostate Cancer, Prostate Adenocarcinoma Trial (drug, other, procedure)

Not yet recruiting
  • Prostate Cancer
  • Prostate Adenocarcinoma
  • (no location specified)
Feb 2, 2023